ADA 2025
20 - 23 June 2025
Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.